Clinical Trial Developments, New Software Platforms, New Technologies, Study Publications, and Upcoming Conferences - Analyst Notes on St. Jude Medical, Varian, ResMed, Masimo and Wright Medical

NEW YORK, May 21, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding St. Jude Medical Inc. (NYSE: STJ), Varian Medical Systems Inc. (NYSE: VAR), ResMed Inc. (NASDAQ: RMD), Masimo Corporation (NASDAQ: MASI) and Wright Medical Group Inc. (NASDAQ: WMGI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2724-100free.

St. Jude Medical Inc. Analyst Notes
On May 13, 2014, St. Jude Medical Inc. (St. Jude Medical) announced the first successful implantation in the Portico™ Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO trial). According to the Company, the PORTICO trial is evaluating the safety and effectiveness of the Portico Transcatheter Aortic Valve System in reducing the risk of death and disabling stroke in patients with high or extreme surgical risk for open-heart valve replacement surgery. The Company informed that the trial is a prospective, multi-center, randomized, controlled clinical trial and will enroll patients at up to 40 U.S. sites. "We have received positive feedback on the advanced features of the Portico valve from the experienced physicians who have used it. The Portico valve is an attractive option that will enable interventional cardiologists and cardiac surgeons who perform TAVR procedures to treat patients who might not otherwise be eligible for surgery," said Dr. Mark Carlson, Chief Medical Officer and Vice President of Global Clinical Affairs at St. Jude Medical. The full analyst notes on St. Jude Medical are available to download free of charge at:

http://www.analystsreview.com/2724-STJ-21May2014.pdf

Varian Medical Systems Inc. Analyst Notes
On May 12, 2014, Varian Medical Systems (Varian) announced the launch of a new release of the Company's Velocity oncology software platform. According to the Company, the updated Velocity oncology software platform gives clinicians a set of new tools that enables the use of diverse types of images and automates time consuming image processing procedures that are fundamental to treating cancer with advanced image-guided radiotherapy or radiosurgery. "We're very pleased with how the integration process is going, and looking forward to sharing this latest Velocity release with Varian customers and others interested in our growing collection of tools for data-driven clinical decision making," said Tim Fox, Associate Vice President, Imaging Informatics at Varian. The full analyst notes on Varian are available to download free of charge at:

http://www.analystsreview.com/2724-VAR-21May2014.pdf

ResMed Inc. Analyst Notes
On May 12, 2014, ResMed Inc. (ResMed) announced the launch of the Astral™ 100 and Astral™ 150 - a new platform of portable, lightweight, and user-friendly life support ventilators, in select European and Asia-Pacific markets. The Company stated that the new generation of Astral life support ventilators offer unparalleled mobility and ease of use for patients suffering from neuromuscular disease, chronic obstructive pulmonary disease (COPD), and other adult and childhood breathing disorders. ResMed informed that with this expanded mobility, the patients who would otherwise be hospitalized may be safely treated away from the hospital for a more enriched life. "We took nothing for granted when designing the Astral family of life support ventilators," said Geoff Neilson, President of ResMed's Respiratory Care Strategic Business Unit. "We listened to patients, physicians, and providers, and addressed their pain points related to ventilator mobility; Astral is a solution that maximizes mobility and functionality." The full analyst notes on ResMed are available to download free of charge at:

http://www.analystsreview.com/2724-RMD-21May2014.pdf

Masimo Corporation Analyst Notes
On May 15, 2014, Masimo Corp. (Masimo) announced the publication of a new study in the Journal of Perinatology. The study showed that there was a 37% lower rate of severe retinopathy of prematurity (ROP) when the neonatal intensive care unit (NICU) at Yale-New Haven Children's Hospital switched to Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry. The Company stated that ROP is an eye disorder that can cause blindness in premature babies, and a 53% lower rate of ROP requiring surgery. "We are very happy to see yet another study showing that when a hospital NICU switches to Masimo SET pulse oximetry, they significantly reduce severe ROP and ROP requiring surgery," said Dr. Augusto Sola, Vice President of Neonatal Medical Affairs for Masimo. The full analyst notes on Masimo are available to download free of charge at:

http://www.analystsreview.com/2724-MASI-21May2014.pdf

Wright Medical Group Inc. Analyst Notes
On May 14, 2014, Wright Medical Group, Inc. (Wright Medical) announced its participation in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at the Grand Hyatt Hotel in New York, New York. The Company informed that it's Senior Vice President and CFO Lance Berry will lead the presentation, which will start at 3:00 p.m. ET. Wright Medical added that a live audio webcast of the presentation, along with the accompanying presentation materials, will be available on the Company's website under the "Investor Info". Additionally the webcast and the presentation materials will also be archived on the same place under the "Investor Presentations". The full analyst notes on Wright Medical are available to download free of charge at:

http://www.analystsreview.com/2724-WMGI-21May2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED